$ATHA
Athira Pharma, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004782 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.927M $6.160M $21.23M
YoY Change 167.28% 58.35% 216.36%
% of Gross Profit
Research & Development $14.46M $12.62M $42.79M
YoY Change 94.22% 143.12% 222.1%
% of Gross Profit
Depreciation & Amortization $154.0K $126.0K $479.0K
YoY Change 37.5% 23850.0%
% of Gross Profit
Operating Expenses $14.46M $18.78M $42.79M
YoY Change 94.22% 106.81% 222.1%
Operating Profit -$23.39M -$64.02M
YoY Change 116.93% 220.19%
Interest Expense $2.000K $103.0K $3.000K
YoY Change -97.5% 28.75% -99.18%
% of Operating Profit
Other Income/Expense, Net $173.0K $2.336M $334.0K
YoY Change 105.95% 79.69% -126.07%
Pretax Income -$20.98M -$16.34M -$54.96M
YoY Change 136.53% 112.19% 175.24%
Income Tax
% Of Pretax Income
Net Earnings -$20.98M -$16.34M -$54.85M
YoY Change 136.63% 112.19% 174.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.56 -$1.49
Diluted Earnings Per Share -$558.1K -$365.2K -$1.486M
COMMON SHARES
Basic Shares Outstanding 37.62M 37.35M 36.92M
Diluted Shares Outstanding 37.59M 36.92M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.5M $253.8M $253.8M
YoY Change -13.37% 37.39% 37.39%
Cash & Equivalents $117.8M $110.5M $110.5M
Short-Term Investments $145.7M $143.2M $143.2M
Other Short-Term Assets $3.394M $4.704M $4.704M
YoY Change -24.58% -26.5% -26.5%
Inventory
Prepaid Expenses
Receivables $2.234M $2.336M $2.336M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $269.2M $260.8M $260.8M
YoY Change -13.61% 35.59% 35.62%
LONG-TERM ASSETS
Property, Plant & Equipment $4.354M $3.757M $5.217M
YoY Change 50.24% 41.83% 44.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.64M $65.94M $65.94M
YoY Change -29.64% -21.03% -21.03%
Other Assets $225.0K $56.00K $56.00K
YoY Change 309.09% -57.58% -44.0%
Total Long-Term Assets $43.85M $71.21M $71.21M
YoY Change -24.2% -18.36% -18.43%
TOTAL ASSETS
Total Short-Term Assets $269.2M $260.8M $260.8M
Total Long-Term Assets $43.85M $71.21M $71.21M
Total Assets $313.0M $332.0M $332.0M
YoY Change -15.27% 18.76% 18.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.431M $567.0K $567.0K
YoY Change -15.17% -51.04% -52.75%
Accrued Expenses $7.743M $8.437M $8.725M
YoY Change 196.67% 170.16% 172.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.471M $9.292M $9.292M
YoY Change 110.61% 110.94% 111.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.554M $1.632M $1.632M
YoY Change -8.59% 81.33% 81.33%
Total Long-Term Liabilities $1.554M $1.632M $1.632M
YoY Change -8.59% 81.33% 81.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.471M $9.292M $9.292M
Total Long-Term Liabilities $1.554M $1.632M $1.632M
Total Liabilities $11.03M $10.92M $10.92M
YoY Change 77.91% 106.85% 106.11%
SHAREHOLDERS EQUITY
Retained Earnings -$116.9M -$95.90M
YoY Change 134.18% 133.65%
Common Stock $420.3M $417.4M
YoY Change 1.75% 32.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $302.0M $321.1M $321.1M
YoY Change
Total Liabilities & Shareholders Equity $313.0M $332.0M $332.0M
YoY Change -15.27% 18.76% 18.74%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$20.98M -$16.34M -$54.85M
YoY Change 136.63% 112.19% 174.88%
Depreciation, Depletion And Amortization $154.0K $126.0K $479.0K
YoY Change 37.5% 23850.0%
Cash From Operating Activities -$16.57M -$18.18M -$43.10M
YoY Change 126.86% 70.52% 78.73%
INVESTING ACTIVITIES
Capital Expenditures $745.0K -$1.027M $1.573M
YoY Change 145.07% -54.36% -32.2%
Acquisitions
YoY Change
Other Investing Activities $24.59M $22.40M -$2.506M
YoY Change -209.78% -119.74% -98.79%
Cash From Investing Activities $23.85M $21.37M -$4.079M
YoY Change -205.01% -118.46% -98.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 210.0K 13.00K 97.09M
YoY Change -99.78% -99.94% -66.84%
NET CHANGE
Cash From Operating Activities -16.57M -18.18M -43.10M
Cash From Investing Activities 23.85M 21.37M -4.079M
Cash From Financing Activities 210.0K 13.00K 97.09M
Net Change In Cash 7.484M 3.209M 49.91M
YoY Change -88.86% -103.05% -14.78%
FREE CASH FLOW
Cash From Operating Activities -$16.57M -$18.18M -$43.10M
Capital Expenditures $745.0K -$1.027M $1.573M
Free Cash Flow -$17.32M -$17.15M -$44.67M
YoY Change 127.59% 103.92% 69.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1261
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001620463
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39503
CY2021 dei Entity Registrant Name
EntityRegistrantName
Athira Pharma, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3368487
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
18706 North Creek Parkway
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 104
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Bothell
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98011
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
83509000
CY2021Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
2336000
CY2020Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
1300000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4704000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6355000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
260799000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
192337000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3757000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2649000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1460000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
936000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
65936000
CY2021 dei City Area Code
CityAreaCode
425
CY2021 dei Local Phone Number
LocalPhoneNumber
620-8501
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
ATHA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
328300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37624058
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Seattle, Washington
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110537000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60625000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
143222000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
124057000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
132000
CY2021Q4 us-gaap Assets
Assets
332008000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95895000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-388000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2020Q4 us-gaap Assets
Assets
279563000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
567000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1158000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8437000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3123000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
288000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9292000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4405000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1632000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
876000
CY2021Q4 us-gaap Liabilities
Liabilities
10924000
CY2020Q4 us-gaap Liabilities
Liabilities
5281000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37379077
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37379077
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32485784
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32485784
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
417363000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
315288000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41042000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
321084000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
274282000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
332008000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279563000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42794000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13286000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21228000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6709000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
64022000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
19995000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-64022000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19995000
CY2021 atha Grant Income
GrantIncome
8835000
CY2020 atha Grant Income
GrantIncome
1321000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
334000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1281000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54853000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19955000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-421000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55274000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19922000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36921172
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11966912
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-19723000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2020 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
10591000
CY2020 atha Issuance Of Common Stock Value During The Period Initial Public Offering Net Of Underwriters Discounts And Commissions
IssuanceOfCommonStockValueDuringThePeriodInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissions
208517000
CY2020 atha Stock Issued During Period Value Conversion Of Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
92537000
CY2020 atha Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1105000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
633000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19955000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
274282000
CY2021 atha Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits
327000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
364000
CY2021 atha Issuance Of Common Stock Value During The Period Initial Public Offering Net Of Underwriters Discounts And Commissions
IssuanceOfCommonStockValueDuringThePeriodInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissions
96762000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4623000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-421000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54853000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
321084000
CY2021 us-gaap Profit Loss
ProfitLoss
-54853000
CY2020 us-gaap Profit Loss
ProfitLoss
-19955000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4623000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
633000
CY2021 us-gaap Depreciation
Depreciation
479000
CY2020 us-gaap Depreciation
Depreciation
2000
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
1401000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-493000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-251000
CY2021 atha Increase Decrease In Unbilled Grant Receivables
IncreaseDecreaseInUnbilledGrantReceivables
1036000
CY2020 atha Increase Decrease In Unbilled Grant Receivables
IncreaseDecreaseInUnbilledGrantReceivables
1300000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1650000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6310000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5150000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2601000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
396000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
64000
CY2020 atha Increase Decrease In Grant Liability
IncreaseDecreaseInGrantLiability
-1500000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43098000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24113000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
299197000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
226837000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
278639000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19053000
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
18052000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1573000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2320000
CY2020 us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
36000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4079000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210068000
CY2021 atha Proceeds From Exercise Of Common Stock Options And Common Stock Warrants
ProceedsFromExerciseOfCommonStockOptionsAndCommonStockWarrants
327000
CY2020 atha Proceeds From Exercise Of Common Stock Options And Common Stock Warrants
ProceedsFromExerciseOfCommonStockOptionsAndCommonStockWarrants
643000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
96762000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
208517000
CY2020 atha Proceeds From Sales Of Convertible Preferred Stock And Stock Warrants Net Of Issuance Costs
ProceedsFromSalesOfConvertiblePreferredStockAndStockWarrantsNetOfIssuanceCosts
81926000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1664000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97089000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
292750000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49912000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58569000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60625000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2056000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110537000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60625000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
331000
CY2020 atha Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
77000
CY2020 atha Proceeds To Common Stock Warrants Issued In Convertible Preferred Stock Financing
ProceedsToCommonStockWarrantsIssuedInConvertiblePreferredStockFinancing
10591000
CY2020 us-gaap Stock Issued1
StockIssued1
4515000
CY2020 atha Recognition Of Warrant Liability In Connection With Convertible Preferred Stock Financing
RecognitionOfWarrantLiabilityInConnectionWithConvertiblePreferredStockFinancing
364000
CY2020 atha Recognition Of Derivative Liability Upon Issuance Of Convertible Notes
RecognitionOfDerivativeLiabilityUponIssuanceOfConvertibleNotes
774000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
92537000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
680000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
975000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">1. Description of Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Athira Pharma, Inc. (the “Company”) was incorporated as M3 Biotechnology, Inc. in the state of Washington on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 31, 2011</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and reincorporated in the state of Delaware on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">October 27, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On September 11, 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_8bc577bb-a5d5-439e-9200-e5befc5a384f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one-for-7.9302</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reverse split of its issued and outstanding common stock, convertible preferred stock, warrants, and stock options.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The par value of the common stock and convertible preferred stock was not adjusted as a result of the reverse stock split. All share and per share amounts in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted for all periods presented to reflect the reverse stock split.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2020, the Company completed its initial public offering of common stock (“IPO”) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">186.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million after deducting underwriting discounts and commissions and offering expenses paid by the Company. In October 2020, the Company sold an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,397,712</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock to the underwriters of the IPO upon partial exercise of the underwriters’ option to purchase additional shares at the initial public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, less underwriting discounts and commissions and offering costs resulting in additional net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the closing of the IPO, all of the Company’s outstanding shares of convertible preferred stock were automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,503,009</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock. Immediately prior to the Company’s IPO, all outstanding common stock warrants were exercised into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,085,334</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock. Additionally, all outstanding Series B convertible preferred stock warrants were remeasured to their fair value. The final remeasurement of the Series B convertible preferred stock warrant liability resulted in a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million loss which was recorded to other income (expense), net. Following remeasurement, all Series B convertible preferred stock warrants automatically net exercised into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">59,093</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock and the corresponding liability was reclassified to additional paid in capital. Following the IPO, there are </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of convertible preferred stock, common stock warrants, or Series B convertible preferred stock warrants outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Follow-on Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2021, the Company completed a follow-on public offering of its common stock. As part of the follow-on offering, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,000,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million from the follow-on offering, after deducting underwriting discounts and commissions and offering costs. In February 2021, the Company sold an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">600,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock to the underwriters of the follow-on public offering upon full exercise of the underwriters’ option to purchase additional shares at the follow-on public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, less underwriting discounts and commissions and offering costs resulting in additional net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since the Company’s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company’s inception through December 31, 2021, it has raised aggregate net cash proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">407.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million primarily from the issuance of its common stock, convertible preferred stock, common stock warrants, and convertible notes. As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">319.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company’s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company’s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based upon the Company’s current operating plan, it estimates that its $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">319.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of cash, cash equivalents, and investments at December 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of the Company’s Annual Report on Form 10-K.</span></p>
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-03-31
CY2021 atha Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-10-27
CY2020Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
On September 11, 2020, the Company effected a one-for-7.9302 reverse split of its issued and outstanding common stock, convertible preferred stock, warrants, and stock options.
CY2021 atha Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants
ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants
407400000
CY2021Q4 atha Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
319700000
CY2021Q4 atha Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
319700000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q4 atha Grant Liability Current
GrantLiabilityCurrent
1500000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
523000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3757000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2649000
CY2021 atha Grant Income
GrantIncome
8835000
CY2020 atha Grant Income
GrantIncome
1321000
CY2021Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
2336000
CY2020Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
1300000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4280000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2720000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1907000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1624000
CY2021Q4 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
807000
CY2021 us-gaap Depreciation
Depreciation
479000
CY2020 us-gaap Depreciation
Depreciation
2000
CY2021Q4 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5723000
CY2020Q4 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1169000
CY2020Q4 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
330000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8437000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3123000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
337000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
124000
CY2021 us-gaap Interest Expense
InterestExpense
3000
CY2020 us-gaap Interest Expense
InterestExpense
367000
CY2020 atha Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
132000
CY2020 atha Change In Fair Value Of Grant Liability
ChangeInFairValueOfGrantLiability
464000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
641000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
334000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1281000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
323000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
108000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
452000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
466000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
480000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
494000
CY2021Q4 atha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
856000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2748000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
548000
CY2021Q4 atha Tenant Improvement Allowance Receivable
TenantImprovementAllowanceReceivable
-280000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1920000
CY2020 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The Series B convertible preferred stock financing triggered the automatic conversion of the Company’s outstanding convertible promissory notes into 512,858 shares of Series B-1 convertible preferred stock based on a price of $7.752 per share (85% of the $9.12 original issuance price of the Series B convertible preferred stock).
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7695922
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6040105
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1974870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4442315
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4623000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
633000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0099
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9091
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8741
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10M13D
CY2021 atha Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Of Options Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOfOptionsGranted
14400000
CY2020 atha Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Of Options Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOfOptionsGranted
4200000
CY2021 atha Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
5700000
CY2020 atha Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3742235
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
1624259
CY2021 atha Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Unit Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted
1392928
CY2021 atha Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Forfeited Cancelled Or Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired
468749
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49275000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1024776
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.83
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
263501
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
465249
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.02
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2270896
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.76
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8306000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1457586
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
16.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y11M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1925000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
813310
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.80
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y18D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6380000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1400000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
271000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3100000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18000000.0
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10200000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M7D
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-54963000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19969000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
110000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
14000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54853000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19955000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0.012
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2020 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Convertible Notes And Derivative Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToConvertibleNotesAndDerivativeLiability
-0.010
CY2020 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Grant Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToGrantLiability
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.022
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.015
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.246
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.216
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19543000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8090000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2166000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1011000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
392000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
295000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
804000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
106000
CY2021Q4 atha Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
426000
CY2020Q4 atha Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
210000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
224000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
72000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23555000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9784000
CY2021Q4 atha Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
324000
CY2020Q4 atha Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
197000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
664000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
489000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
988000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
686000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22567000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9098000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13500000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4300000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
80700000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
337000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
239000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
385000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
98000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
722000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
337000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2633673
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1983069
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36499004
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36773100
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05

Files In Submission

Name View Source Status
0000950170-22-004782-index-headers.html Edgar Link pending
0000950170-22-004782-index.html Edgar Link pending
0000950170-22-004782.txt Edgar Link pending
0000950170-22-004782-xbrl.zip Edgar Link pending
atha-20211231.htm Edgar Link pending
atha-20211231.xsd Edgar Link pending
atha-20211231_cal.xml Edgar Link unprocessable
atha-20211231_def.xml Edgar Link unprocessable
atha-20211231_htm.xml Edgar Link completed
atha-20211231_lab.xml Edgar Link unprocessable
atha-20211231_pre.xml Edgar Link unprocessable
atha-ex10_27.htm Edgar Link pending
atha-ex10_28.htm Edgar Link pending
atha-ex23_1.htm Edgar Link pending
atha-ex31_1.htm Edgar Link pending
atha-ex31_2.htm Edgar Link pending
atha-ex32_1.htm Edgar Link pending
atha-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img103422717_0.jpg Edgar Link pending
img103422717_1.jpg Edgar Link pending
img103422717_10.jpg Edgar Link pending
img103422717_11.jpg Edgar Link pending
img103422717_12.jpg Edgar Link pending
img103422717_13.jpg Edgar Link pending
img103422717_14.jpg Edgar Link pending
img103422717_15.jpg Edgar Link pending
img103422717_16.jpg Edgar Link pending
img103422717_17.jpg Edgar Link pending
img103422717_18.jpg Edgar Link pending
img103422717_19.jpg Edgar Link pending
img103422717_2.jpg Edgar Link pending
img103422717_20.jpg Edgar Link pending
img103422717_21.jpg Edgar Link pending
img103422717_3.jpg Edgar Link pending
img103422717_4.jpg Edgar Link pending
img103422717_5.jpg Edgar Link pending
img103422717_6.jpg Edgar Link pending
img103422717_7.jpg Edgar Link pending
img103422717_8.jpg Edgar Link pending
img103422717_9.jpg Edgar Link pending
img25408676_0.jpg Edgar Link pending
img25408676_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending